Prostate cancer treatment moving towards personalized approach with six new drugs in the pipeline that address this need, says GlobalData

Although options for prostate cancer have historically been limited, the late-stage prostate cancer pipeline holds promise for the future of this second most common cancer among men, according to GlobalData a leading data and analytics company.

GlobalData predicts the launch of 12 new agents among the eight major markets* (8MM), covering eight mechanisms of action (MOAs), six of which will be brand new to this market. Novel MOAs for prostate cancer include Poly (ADP-ribose) polymerase (PARP) inhibitors, one Akt inhibitor, one radioligand, and checkpoint inhibitors.

Heather Leach, Director of Oncology and Hematology at GlobalData, commented: “Among the most significant developments is the promise for precision medicine within this indication. Although other cancers have benefited from the incorporation of predictive biomarkers into the treatment paradigm, such as in breast cancer or non-small cell lung cancer, prostate cancer has lagged in this area.”

Image

IMAGE FOR PUBLICATION:  Late-stage clinical development pipeline for prostate cancer, 2019

However, there are six new therapies that hold potential to change this, including all four PARP inhibitors, ipatasertib (an Akt inhibitor), and 177Lu-PSMA-617 (a radioligand), which are in development for patients with homologous recombination deficiencies (HRD), phosphatase and tensin homolog (PTEN) loss, and prostate-specific membrane antigen (PSMA) expression, respectively.

Leach concludes: “Between these agents, GlobalData expects that nearly all prostate cancer cases will hold a biomarker amenable to treatment with at least one of these agents”.

* (8MM); US, France, Germany, Italy, Spain, UK, Japan, and China)

More Media